Current Clinical Evidence on Nose-to-Brain Drug Delivery

Area of Science:

• Neuroscience
• Pharmacology
• Drug Delivery Systems

Background:

• Intranasal delivery enables direct nose-to-brain drug transport, bypassing the blood-brain barrier.
• This pathway is promising for treating neurological disorders like Alzheimer's, Parkinson's, and epilepsy.
• Existing FDA-approved intranasal products for CNS disorders highlight clinical relevance.

Purpose of the Study:

• To review the potential of intranasal drug delivery for direct brain transport.
• To highlight clinical evidence and FDA-approved applications of this delivery strategy.
• To discuss the role of nanoformulations and specialized devices in enhancing efficacy.

Main Methods:

• Review of preclinical and clinical studies on intranasal drug delivery.
• Analysis of existing FDA-approved intranasal medications for CNS disorders.
• Examination of studies combining intranasal delivery with nanoformulations and devices.

Main Results:

• Intranasal delivery shows potential for treating various neurological and psychiatric conditions.
• Clinical studies with rivastigmine, insulin, and olanzapine demonstrate encouraging results.
• Combination with nanoformulations and specialized devices enhances olfactory deposition and brain bioavailability.

Conclusions:

• Intranasal delivery is a promising, non-invasive strategy for direct brain drug transport.
• Further clinical studies are needed to confirm long-term safety and efficacy.
• This approach may improve patient adherence and therapeutic outcomes for neurological disorders.